Last change of this site: 02 August 2005

Program

9th and 10th of September

Gorlaeus Laboratories
Leiden University
Einsteinweg 55
2333 CC Leiden

Scientific Congress on Cannabinoids in Medicine

Overview of the Program

 

Friday, September 9

08:00 – 08:45

Registration

08:45 – 09:00

Greetings

09:00 – 10:30

First Session (Clinical Studies)

10:30 – 11:00

Break

11:00 – 12:30

Second Session (Political and Social Issues)

12:30 – 14:00

Lunch

14:00 – 15:00

IACM General Meeting & IACM Award

15:00 – 15:45

Review (Multiple Sclerosis & ALS)

15:45 – 16:15

Break

16:15 – 17:45

Third session (Basic Research)

17:45

End

18:00

Bus to Kurhaus Scheveningen (Evening dinner)

 

Saturday, September 10

08:30 – 09:00

Registration

09:00 – 10:30

First session (Application and Pharmacokinetics)

10:30 – 11:00

Break

11:00 – 12:30

Second session (Miscellaneous)

12:30 – 14:00

Lunch

14:00 – 15:00

Poster session

15:00 – 15:45

Review (Gastrointestinal Inflammation)

15:45 – 16:15

Break

16:15 – 17:45

Third session (Side Effects, Risks and Problems)

17:45

End of the meeting

 

 

Detailed Program

 

Friday, September 9

 

08:00 – 08:45

Registration

 

08:45 – 09:00

Greetings

 

09:00 – 10:30

First Session (Clinical Studies)

 

09:00 – 09:15

Philip Robson, Derick Wade, Petra Makela, Heather House, Cynthia Bateman

 

Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long term treatment with no evidence of tolerance

09:15 – 09:30

Donald Abrams

Cannabis in HIV-related peripheral neuropathy: results of a randomized

placebo-controlled trial

09:30 – 09:45

F. Markus Leweke, Dagmar Koethe, Christoph W. Gerth, Brit M. Nolden, Daniela Schreiber, Anita Hänsel, Miriam A. Neatby, Antje Juelicher, Martin Hellmich, Joachim Klosterkötter

Cannabidiol as an antipsychotic. a double-blind, controlled clinical trial on Cannabidiol vs. Amisulpride in acute schizophrenia.

09:45 – 10:00

Andrea Pelliccia, Gianpaolo Grassi, Angela Romano, Paolo Crocchiolo

Treatment with CBD in oily solution of drug-resistant paediatric epilepsies

10:00 – 10:15

Jeffrey Y. Hergenrather, Tod H. Mikuriya, David Bearman

Clinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with Crohn's disease

10:15 – 10:30

Gernot Ernst, Claudia Denke, Marcus Reif, Martin Schnelle, Hartmut Hagmeister

Standardized cannabis extract in the treatment of postherpetic neuralgia – a randomized, double-blind, placebo-controlled cross-over study

 

10:30 – 11:00

Break

 

11:00 – 12:30

Second session (Political and Social Issues)

 

11:00 – 11:15

Marco van de Velde

Two years of experience with legal production and distribution of medicinal cannabis in the Netherlands

11:15 – 11:30

Annemarie Janse, Nancy Breekveldt-Postma, Joelle Erkens, Ron Herings

Medicinal cannabis in the Netherlands

11:30 – 11:45

Louise Déry

Canadian Medical Marijuana Research Program: main purpose and accomplishments

11:45 – 12:00

Dolors Capellŕ, Marta Duran, Sergio Abanades

The therapeutic use of cannabis project in Catalonia: information, prescription and research

12:00 – 12:15

Dale Gieringer

The growth of cannabis medicine in the U.S.: practice & usage in a semi-legal regime

12:15 – 12:30

Mark Gibson

Canna-Biz Chocolate, production, and despatch to sufferers of multiple sclerosis

 

12:30 – 14:00

Lunch

 

14:00 – 15:00

IACM General Meeting & IACM Award

 

15:00 – 15:45

Review

 

David Baker

Potential use of cannabinoids in multiple and amyotrophic lateral sclerosis

 

 

15:45 – 16:15

Break

 

16:15 – 17:45

Third session (Basic Research)

 

16:15 – 16:30

Ester Fride, Tatiana Bregman, Oded Edelheit, Israel Hanukoglu, and Amiram Raz

Cannabinoids and cystic fibrosis (CF): different regulation of the endocannabinoid CB receptor system in CF mice

16:30 – 16:45

Natalya M. Kogan, Manuel Guzman, Ester Priel, Michael Schlesinger, Gergana Marincheva, Ronen Beeri and  Raphael Mechoulam

Quinone type cannabinoids as anticancer compounds

16:45 – 17:00

Krisztina Monory, Federico Massa, Heike Blaudzun, Giovanni Marsicano, Beat Lutz

The role of different neuronal populations in the pharmacological actions of delta-9-tetrahydrocannabinol

17:00 – 17:15

Dagmar Koethe, Christoph W. Gerth, Daniela Schreiber, Brit M. Nolden, Sonja Gross, Antje Juelicher, Joachim Klosterkötter, Andrea Giuffrida, Daniele Piomelli, F. Markus Leweke

The endocannabinoid anandamide in CSF is related to the patterns of cannabis use in first-episode schizophrenia

17:15 – 17:30

Philipp-Alexander Brand,  Andrea Paris, Jens Scholz, Kristina Lueken;

Peter Tonner

Cannabinoids and their interaction with anesthesia in mice

17:30 – 17:45

Roger G. Pertwee, Lesley A. Stevenson, Ruth A. Ross, Martin R. Price,

Gemma L. Baillie, Kerrie N. Wease and Adčle Thomas

The plant cannabinoid, delta-9-tetrahydrocannabivarin, selectively antagonizes R-(+)-WIN55212, anandamide and delta-9-tetrahydrocannabinol

 

17:45

End

 

18:00

Bus to Kurhaus Scheveningen (Evening dinner)

 

 

Saturday, September 10

 

08:30 – 09:00

Registration

 

09:00 – 10:30

First session (Application and Pharmacokinetics)

 

09:00 – 09:15

L. Zuurman, C. Roy, A. Hazekamp, R. Schoemaker, J. den Hartigh, J.C.M.E. Bender, R. Verpoorte, J.L. Pinquier, A.F. Cohen, J.M.A. van Gerven

Effect of THC administration in humans: methodology study for further pharmacodynamic studies with cannabinoid agonist or antagonist

09:15 – 09:30

Tjeert Mensinga, Irma de Vries, Maaike Kruidenier, Wim Scholten, and Jan Meulenbelt

Pharmacokinetics and effects of cannabis at higher exposure levels

09:30 – 09:45

Arno Hazekamp, Renee Ruhaak, Lineke Zuurman, Joop van Gerven, Rob Verpoorte

Optimized administration of THC for clinical use by vaporizing

09:45 – 10:00

Donald Abrams

Vaporization as a smokeless cannabis delivery system: results of a

randomized comparative trial

10:00 – 10:15

Thomas Nadulski, Fritz Pragst, Gordon Weinberg, Patrik Roser, Martin Schnelle, Eva-Maria Fronk and Andreas Michael Stadelmann

Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) after oral application of THC vs. standardized cannabis extract

10:15 – 10:30

Floris de Jong, Frederike Engels, Jaap Verweij, and Ron Mathijssen

Influence of medicinal cannabis on the pharmacokinetics of the anti-cancer agents docetaxel and irinotecan

 

10:30 – 11:00

Break

 

11:00 – 12:30

Second session (Miscellaneous)

 

11:00 – 11:15

Richard E. Musty and Jose Andre de Sousa Crippa

Potential therapeutic effects of cannabinoids on anxiety, a review  

11:15 – 11:30

Marieke van Haaster

Facts and phantasy, cannabis and MS

11:30 – 11:45

Yosef Sarne, Bella Tselnicker, Chagi Pick and Ora Keren

Dissociating between the neuroprotective and neurotoxic effects of THC (delta-9 tetrahydrocannabinol)

11:45 – 12:00

Anita Holdcroft, Caroline Doré, and Susan Tebbs

Qualitative measures of mood and sensory responses to cannabis extract (Cannador) in THE CANPOP Study

12:00 – 12:15

Christian Giroud, Frank Sporkert, Arno Hazekamp, Marc Augsburger, Florianne Monnet-Tschudi, Patrice Mangin

Chromatographic-mass spectrometry procedures for determination of cannabinoids in blood and brain tissues. Application to forensic cases and pharmacological studies

12:15 – 12:30

Jörg Fachner

 

Comparing topographic EEG brainmapping changes of cannabis induced and sound-trance induced altered state of consciousness

 

12:30 – 14:00

Lunch

 

14:00 – 15:00

Poster session

 

15:00 – 15:45

Review

 

Vincenzo Di Marzo

The role of endocannabinoids in gastrointestinal inflammation

 

15:45 – 16:15

Break

 

16:15 – 17:45

Third session (Side Effects, Risks and Problems)

 

16:15 – 16:30

John Zajicek

Lessons learnt from the CAMS study

16:30 – 16:45

Aaron B. Ilan, Alan Gevins, Kemi Role, Hector Vizoso, Donald I. Abrams

The cognitive neurophysiological effects of medicinal marijuana in HIV+ patients with peripheral neuropathy

16:45 – 17:00

Sergio Abanades

Cannabis and neuropsychological performance: results form a 3 year follow-up study

17:00 – 17:15

Franjo Grotenhermen, Gero Leson, Günter Berghaus, Olaf Drummer, Hans-Peter Krüger, Marie Longo, Herbert Moskowitz, Bud Perrine, Jan Ramaekers, Alison Smiley, Rob Tunbridge

Developing per se laws for driving under the influence of cannabis (DUIC)

17:15 – 17:30

Emmanuel S. Onaivi

 

An endocannabinoid hypothesis of substance abuse

17:30 – 17:45

Ethan B. Russo

Sativex adverse event profile and comparison with Marinol and “medical grade cannabis” in clinical studies

 

17:45

End of the Meeting

 

 

 

Posters (Poster Session on Saturday, 14:00 – 15:00)

 

Marta Duran, Eva Montané, Xavi Vidal, Joan-Ramon Laporte, Dolors Capellŕ

 

Cannabinoids as antispastic agents for multiple sclerosis: a qualitative systematic review

Arno Hazekamp, Rob Verpoorte

 

Solubilizing THC in water by cyclodextrins

Jonathon Arnold, Michelle Holland, Nathan Gunasekaran and John Allen